Amgen aims to treat liver, kidney diseases with obesity drug
Adds details and background throughout
By Puyaan Singh
Sept 4 (Reuters) -Amgen AMGN.O will test its obesity drug candidate in patients at risk of weight-relatedconditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert Bradway said on Wednesday.
California-based Amgen's plan to test obesity drug MariTide for other conditions comes as its peers, such as Eli LillyLLY.N and Novo Nordisk NOVOb.CO, test their obesity medications to treat different diseases.
Lilly is testing its obesity drug, Zepbound, in patients with heart failure and chronic kidney disease, while Novo Nordisk's Wegovy was approved to lower major heart risks and strokes.
Some analysts have said the market for new weight-loss drugs could exceed $150 billion by the early 2030s.
Speaking at a Morgan Stanley healthcare conference, Bradway describedMariTide as a next-generationobesity drug due to its different mechanism of action and less frequent dosing compared to blockbuster medicines such asZepbound and Wegovy, which require weekly-dosing.
"Our medicine is likely to be administered monthly or less frequently than that, so that means we're giving a quarter of the number of injections as the two competitors that are on the market now, each month," he said.
Lilly and Novo have been struggling to produce enough of their obesity medications to meet the soaringdemand, though Lilly ramped up its manufacturing in the last quarter.
"Some of their supply challenge is a function of the number of injections they're having to provide. We start with the benefit of doing a quarter of what they're looking to do," Bradway said.
The company had said in August it expects to have initial data from a mid-stage trial of MariTide late this year.
Reporting by Puyaan Singh; Editing by Shreya Biswas
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
